Search PubMed⌕ Search

Biomedical subjects

W Stremmel

Publications and source records attributed to W Stremmel.

313 records · Page 18Linked to original sources

Transmembrane transport of fatty acids in the heart.

Although fatty acid uptake by the myocardium is rapid and efficient, the mechanism of their transmembrane transport has been unclear. Fatty acids are presented to the plasma membrane of cardiomyocytes as albumin complexes within the plasma. Since albumin is not taken up by the cells, it was postulated that specific high affinity binding sites at the sarcolemma may mediate the dissociation of fatty acids from the albumin molecules, before they are transported into the cells. In studies with a representative long-chain fatty acid, oleate, it was in fact shown that fatty acids bind with high affinity to isolated plasma membranes of rat heart myocytes revealing a KD of 42 nM. Moreover, a specific membrane fatty acid-binding protein (MFABP) was isolated from these membranes. It had a molecular weight of 40 kD, an isoelectric point of 9.0, and lacked carbohydrate or lipid components. Binding to a specific membrane protein might represent the first step of a carrier mediated uptake process. Therefore, the uptake kinetics of oleate by isolated rat heart myocytes was determined under conditions where only cellular influx and not metabolism occurred. Uptake revealed saturation kinetics and was temperature dependent which were considered as specific criteria for a facilitated transport mechanism. For evaluation whether uptake is mediated by MFABP, the effect of a monospecific antibody to this protein on cellular influx of oleate was examined. Inhibition of uptake of fatty acids but not of glucose by the antibody to MFABP indicated the physiologic significance of this protein as transmembrane carrier in the cellular uptake process of fatty acids.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

The membrane fatty acid-binding protein is not identical to mitochondrial glutamic oxaloacetic transaminase (mGOT).

For evaluation whether the membrane fatty acid-binding protein is related to mGOT, studies on the structure and function of both purified proteins were performed. Physicochemical characterization revealed that both proteins are different: the membrane fatty acid-binding protein has a molecular weight of 40 kD and a pI of 8.5-9.0, whereas rat mGOT has a molecular weight of 44 kD and a pI of 9.5-10.0. According to this distinct differences, they migrated separately on 2-dimensional electrophoresis. Furthermore, monospecific antibodies against the membrane fatty acid binding protein did not react with rat mGOT. In co-chromatography studies only the membrane fatty acid-binding protein showed affinity for long chain fatty acids, but not mGOT. Moreover, membrane binding studies were performed with the monospecific antibody to the membrane fatty acid binding protein. The inhibitory effect of this antibody on plasma membrane binding of oleate was reversed after preabsorption of the antibody with the membrane fatty acid binding protein, but was not affected after preabsorption with mGOT. These results indicate that the membrane fatty acid binding protein and mGOT are structurally and functionally not related. The data also support the significance of this membrane protein in the plasma membrane binding process of long chain fatty acids.

Animals↗

His1069Gln and six novel Wilson disease mutations: analysis of relevance for early diagnosis and phenotype.

In the present study we examined 33 German and 10 Cuban unrelated Wilson disease (WND) index patients and their relatives. The common His1069Gln mutation accounted for 42% of all WND chromosomes in the German series and the haplotype C was found to be highly predictive for this mutation. Six WND gene mutations have not been described previously and involved a splice site at intron 18 (3903 + del1G), a termination codon in the copper-binding region of exon 2 (Cys271X), and missense mutations in transmembrane region 2 (Gly710Ala), in transmembrane region 3 (Tyr741Cys), in the DKTGT motif (Thr1031Ile) and in the ATP loop region (Gly1176Arg). In 15 German WND index patients and three sibs both WND mutations could be determined and a genotype-phenotype correlation was attempted. Patients homozygous for the His1069Gln mutation showed almost the complete range of clinical presentations, and thus in our study this mutation is not associated with a late, neurological presentation.

Base Sequence↗

Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma.

BACKGROUND: The purpose of this retrospective study was to determine the response rate and effect on survival of chemotherapy with epirubicin in non-resectable advanced hepatocellular carcinoma (HCC). METHODS: Fifty-two patients with non-resectable disease were treated with epirubicin. A treatment cycle consisted of 20 mg/m(2) i.v. on days 1, 8 and 15 and was repeated every 4 weeks to a maximum dose of 1,000 mg/m(2). Forty-four patients were eligible for analysis. RESULTS: Out of 44 patients, 1 (2.3%) achieved a complete response, 3 (6.8%) had partial responses and 16 (36%) had stable disease (SD). For patients with successful disease control (complete and partial responders and patients with SD), the median survival was 16.2 months; for non-responders, it was 6.1 months (p < 0.003). Eight (88.9%) of 9 patients with alpha-fetoprotein (AFP) levels <50 microg/l achieved successful disease control compared to 12 (34.9%) out of 35 patients with initially elevated AFP (p < 0.0001). CONCLUSION: Epirubicin appears to be an active therapeutic option for patients with non-resectable HCC. Especially the subgroup of patients with low levels of AFP may benefit from this treatment.

Adult↗

The diagnostic value of multi-modality evoked potentials in Wilson's disease.

19 patients with a neurological manifestation of Wilson's disease (WD), most of them with long-term disease (> 10 yr), underwent clinical, psychometrical and electrophysiological evaluation in order to test whether there is a correlation of psychometrical and evoked potential (EP) abnormalities with a semiquantitative clinical score ranging from no (0) to severe (3) symptoms. The following EPs were recorded: acoustically evoked event-related (ERPs), somato-sensory (SSEPs), visually (VEPs) and brainstem evoked potentials (BSEPs). Results were compared with the data of an age- and sex-matched control group. 89% of the patients revealed clinical signs of basal ganglia dysfunction, 11% oculomotor or cerebellar symptoms, but none of the individuals had any clinical hint for visual pathway affection. Psychometrically, 100% had mood disturbances without definite intellectual decline. In EP-recordings, 100% showed ERP, 58.0% SSEP and 53% VEP and BSEP abnormalities. VEP and BSEP measurements did not correlate with the clinical score. There was only a weak correlation of SSEP (right-side)- and ERP-amplitude reduction with the clinical total score. The only significant correlation was found between the clinical total score and the time dependent psychometrical tests. Thus, there is a fairly high percentage of subclinical cerebral impairment in Wilson patients with long-term disease detectable by ERP-recordings which do, however, not correlate with the clinical status of the patients.

Adult↗